Supplementary Material 30 Cost effectiveness scenario analysis – exponential 10% decay in efficacy per annum

| | Costs | QALYs | - | Incremental net health benefit (95% CI) | | |
|----------------|------------------|----------------------|---------------------------------------|---|----------------|----------------|
| | (95% CI) | (95% CI) | ICER | k=£15,000 | k=£20,000 | k=£30,000 |
| | [P(most costly)] | | [Probability of being cost-effective] | | | |
| | | | | | | |
| Control | £642.06 | 17.79359 | | - | - | - |
| | (507.14, 798.4) | (17.77337, 17.81535) | | - | - | - |
| | [0.085] | [0] | | [0] | [0] | [0] |
| SWAL only | £691.19 | 17.83321 | Ext dominated | 0.036 | 0.037 | 0.038 |
| | (563.3, 846.93) | (17.80038, 17.86327) | | (0.001, 0.074) | (0.004, 0.073) | (0.005, 0.072) |
| | [0.216] | [0.007] | | [0.016] | [0.013] | [0.012] |
| SWAL plus desk | £747.60 | 17.88543 | £1,080.27 | 0.085 | 0.087 | 0.088 |
| | (641.42, 868.39) | (17.85625, 17.91152) | | (0.045, 0.126) | (0.048, 0.126) | (0.048, 0.126) |
| | [0.699] | [0.993] | | [0.984] | [0.987] | [0.988] |